Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Relay Therapeutics (Nasdaq: RLAY) recently closed its initial public offering, selling 23 million shares at $20.00 each, generating $460 million in gross proceeds. This includes the full exercise of the underwriters’ option for an additional 3 million shares. The shares began trading on July 16, 2020. The offering was managed by J.P. Morgan, Goldman Sachs, Cowen, and Guggenheim Securities. Relay Therapeutics focuses on precision medicine and enhancing small molecule therapeutic discovery in oncology using its innovative Dynamo platform.
- Raised $460 million for growth initiatives and operations.
- Shares began trading on Nasdaq providing liquidity to investors.
- Focus on enhancing small molecule therapeutic discovery could lead to future revenue growth.
- None.
CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the closing of its initial public offering of 23,000,000 shares of its common stock, including 3,000,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of
J.P. Morgan, Goldman Sachs & Co. LLC, Cowen, and Guggenheim Securities acted as joint book-running managers for the offering.
A registration statement relating to these securities has been filed and was declared effective by the Securities and Exchange Commission on July 15, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204; Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, telephone: 631-274-2806 and Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, Relay Therapeutics aims to effectively drug protein targets that have previously been intractable, with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company’s Dynamo platform integrates an array of leading-edge experimental and computational approaches to provide a differentiated understanding of protein structure and motion to drug these targets.
Contact
Investors:
Pete Rahmer, Head of Investor Relations
prahmer@relaytx.com
Media:
Dan Budwick
1AB Media
973-271-6085
dan@1abmedia.com
FAQ
What was the share price during Relay Therapeutics' IPO?
How many shares were offered in Relay Therapeutics' IPO?
What are the gross proceeds from Relay Therapeutics' IPO?
When did Relay Therapeutics begin trading on Nasdaq?
Who managed Relay Therapeutics' IPO?
